The Week In... Pharma (20-24/07)
  • Posted on: 24/07/2020
  • Category: Industry

The Week In... Pharma (20-24/07)

UK announces COVID-19 vaccine deals with BioNTech/Pfizer and Valneva, Chimnay Bhatt becomes UK MD of Novartis, GSK and CureVac form mRNA tech collaboration, and Teva UK launch Ajovy migraine injector pen.

Interested in Star’s innovative outsourcing and resourcing solutions?

Contact Operations Director, Mark Ward, on 07872 105 540 or email mark.ward@starmedical.co.uk.

On the hunt for a new role, or just curious?

Visit our candidate page, submit your CV to candidates@starmedical.co.uk, or give our offices a ring!

UK announces COVID-19 vaccine deals with BioNTech/Pfizer and Valneva

The UK has secured 90 million doses of two different COVID-19 vaccines from BioNTech/Pfizer and Valneva, with an option of 40 million doses if they check out in trials.

GSK and CureVac form mRNA tech collaboration

GlaxoSmithKline and CureVac have signed a strategic collaboration agreement for research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens.

Chimnay Bhatt takes Novartis’ top UK job as Haseeb Ahmad makes step up

Following the appointment of Haseeb Ahmad to the role of global head of value and access and commercial development, Chinmay Bhatt has taken on the position of managing director UK, Ireland & Nordics for Novartis (NOVN: VX).

UK launch for Ajovy injector pen

Teva UK has launched a pre-filled pen for Ajovy (fremanezumab) injection, offering patients with migraine a more convenient and flexible dosing option than with a syringe, which can be self-administered in the home.

Biocon announces digital diabetes tie-up with Voluntis

Biocon has announced a deal with digital therapy specialist Voluntis, aiming to create personalised care for people with type 2 diabetes taking biosimilar insulins.

While you’re here…

…and are interested in our content, why not sign up to our newsletter?

It’s just below.